NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults

Press/Media: Research

Period10 Jul 2024

Media contributions

1

Media contributions

  • TitleNICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
    Media name/outletYahoo Finanzas
    Media typeWeb
    Country/TerritoryUnited States
    Date10/07/24
    PersonsRichard Weller
View all 1
View less